Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Donut Hole Politics: Patient Assistance Under Part D

This article was originally published in RPM Report

Executive Summary

Big pharma wants to help pick up the costs for patients reaching the coverage gap under Medicare's drug benefit. Medicare's watchdogs at the Inspector General's office are skeptical, but the pharma companies are being persistent.

You may also be interested in...

Co-pay Coupons and the ACA: Despite HHS Ruling, Insurers Still Hold The Cards

The Obama Administration OKs the use of co-pay cards for brand prescription drugs in the ACA-created insurance exchanges. One prominent Republican intends to investigate the decision. But insurers and PBMs can decide whether or not to accept them—a fact being lost in the debate.

"Dollars for Donuts" Deal Revisited: What Pharma Got

A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.

The New Part D: "Dollars for Donuts" Becomes Discounts For Data

The pharmaceutical industry's 50% donut hole discount worked out exactly as planned in the context of shaping the health care reform debate. The implementation of the new program is a different story. The program created by CMS doesn't look anything like industry would have hoped-but manufacturers have no choice but to play by CMS' rules, and try to make it work for them anyway.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts